Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Kelch-like ECH-associated protein 1–Nuclear factor erythroid 2-related factor 2 interaction** is a critical cytoplasmic regulatory mechanism that controls cellular responses to oxidative and electrophilic stress. Under basal conditions, **Keap1** binds **Nrf2** via two motifs (ETGE and DLG) on Nrf2. This binding recruits the Cul3-Rbx E3 ubiquitin ligase complex through Keap1’s BTB domain, resulting in polyubiquitination and proteasomal degradation of Nrf2. Upon exposure to oxidative or electrophilic agents—which modify cysteine residues on Keap1—this inhibitory complex dissociates or changes conformation. As a result, newly synthesized Nrf2 escapes degradation, translocates into the nucleus, binds antioxidant response elements (AREs), and drives transcriptional activation of numerous cytoprotective genes involved in glutathione synthesis, detoxification enzymes like HO‑1and GSTs, NADPH regeneration pathways among others. Disruption or pharmacological inhibition of this protein-protein interface is being explored therapeutically for diseases where enhanced antioxidant defense is beneficial—including neurodegeneration and inflammation—as well as targeted modulation in cancer where aberrant pathway activation can contribute to tumor progression or therapy resistance.
Inhibition of the Keap1–Nrf2 protein-protein interaction, leading to stabilization and nuclear translocation of Nrf2, which activates antioxidant response element (ARE)-driven gene expression
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like ECH-associated protein 1–Nuclear factor erythroid 2-related factor 2 interaction (Keap1–Nrf2 interaction).